All In Biotech

Free tool

FAERS Monitor: Tazverik

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211723 or its brand name (Tazverik, Tazemetostat Hydrobromide). Reports on generic versions are filed under their own applications.

Reports

1,622

Serious

721

44% of reports

Hospitalization

324

Death reported

216

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use335
  • fatigue326
  • disease progression305
  • nausea235
  • product dose omission issue212
  • death132
  • diarrhoea123
  • decreased appetite97
  • vomiting95
  • asthenia83
  • constipation80
  • headache74
  • covid-1972
  • drug ineffective71
  • alopecia69

Reports by year received

View as table
YearReports
20173
201811
20196
202081
2021256
2022395
2023316
2024205
2025242
2026107

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,537 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
disease progressionSignal30533.530.39,616
product dose omission issueSignal2129.48.31,595
fatigueSignal3265.44.91,219
decreased appetiteSignal975.44.5349
covid-19Signal725.34.2250
off label useSignal3355.04.51,101
constipationSignal804.83.8236
alopeciaSignal694.63.6190
nauseaSignal2353.93.4512
astheniaSignal832.92.3101
vomitingSignal952.62.296
diarrhoeaSignal1232.52.1110
death1322.01.766
headache741.51.213
drug ineffective710.70.610

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.